INFOLINK: Clinical Trial News
In a study published in the January 2008 issue of the Journal of Wound Care, researchers from Sweden report their findings on the presence and severity of cardiac disease in persons with chronic diabetic foot ulcers. Clinical examination, toe blood-pressure measurements, and standard echocardiography were performed on 80 patients with chronic diabetic foot ulcers, and these patients were examined. A total of 69% of participants had a history of myocardial infarction and/or hypertension and/or heart failure; 78% had signs of left ventricular dysfunction and/or left ventricular hypertrophy and/or diastolic dysfunction; and 76% of patients without a history of cardiovascular disease had signs of cardiac dysfunction on echocardiography. Researchers concluded that the study indicates chronic diabetic foot ulcers should be considered a sign of cardiac disease, and further research is warranted.
Source: Löndahl M, Katzman P, Fredholm O, Nilsson A, Apelqvist J. Is chronic diabetic foot ulcer an indicator of cardiac disease? J Wound Care 2008:17(1):12-6.
Immunosyn Corporation, La Jolla, CA, announced that the first phase of a formal "Proof of Concept Trial" for the biopharmaceutical SF-1019 has been successfully completed in Europe for treatment of diabetic ulcers. The primary purpose of the "Proof of Concept Trial" was to further evaluate the safety and efficacy of SF-1019 in the treatment of diabetic ulceration and its effect on diabetic polyneuropathy in type 1 diabetes mellitus by both subcutaneous injection and by topical application.
The next phase of trials is expected to be completed during the first half of 2008.
▴ Information:http://www.immunosyn.com© 2008 Lippincott Williams & Wilkins, Inc.